戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  improved therapies for benign and malignant hematologic disease.
2 in patients with malignant and non-malignant hematologic disease.
3 -4.3) for trauma to 8.7 (95% CI, 6.8-11) for hematologic disease.
4 provide insights into inherited and acquired hematologic disease.
5 lantation (HSCT) is often exploited to treat hematologic disease.
6 l transplantation, in patients with advanced hematologic disease.
7 te hematopoiesis but may also be relevant to hematologic disease.
8 geted therapy as a new treatment modality in hematologic disease.
9 en given to its effect on the development of hematologic disease.
10 d diagnosis and treatment for this important hematologic disease.
11 f choice for treatment of intractable benign hematologic disease.
12 ne of the affected patients had a history of hematologic disease.
13 y to improve the safety of HSCT for treating hematologic diseases.
14  in the context of splicing dysregulation in hematologic diseases.
15 n receptor (CAR) cells is very effective for hematologic diseases.
16 nd possible clinical manifestations in other hematologic diseases.
17 n the microbiota's role in hematopoiesis and hematologic diseases.
18 antation, a potentially curative therapy for hematologic diseases.
19 ved as a curative modality for patients with hematologic diseases.
20  thought to contribute to the development of hematologic diseases.
21 at promise for cell-based therapies to treat hematologic diseases.
22  investigation and for clinical diagnosis of hematologic diseases.
23 is a curative procedure for life-threatening hematologic diseases.
24 cyte (MN) recruitment in immune-mediated and hematologic diseases.
25 s too low for effective gene therapy of most hematologic diseases.
26 deal treatment strategy for many genetic and hematologic diseases.
27 he treatment of a large number of congenital hematologic diseases.
28 th laparoscopic splenectomy in patients with hematologic diseases.
29 stics hold promise for improved care of rare hematologic diseases.
30 berrant PKA signaling in the pathogenesis of hematologic diseases.
31 of these genes in malignant and nonmalignant hematologic diseases.
32 ng nonmalignant non-primary immunodeficiency hematologic disease (15.4%; p = 0.020), metabolic disord
33 inhibition in prototypic complement-mediated hematologic diseases, (3) hematologic entities under inv
34 rge and were alive and in remission of their hematologic disease after a follow-up of 18 (range, 5-30
35  efforts to better understand the origins of hematologic disease and engineer HSCs from differentiati
36  of patients with several types of malignant hematologic disease and hematologic disorders; however,
37 based assays tended to show earlier onset of hematologic disease and shorter survival.
38                    The most common ones were hematologic diseases and chromosomal abnormalities.
39 und in PB lymphocytes of patients with other hematologic diseases and heavy transfusion burdens or in
40 aving therapy for malignant and nonmalignant hematologic diseases and metabolic disorders.
41 nd therapy of cardiovascular, pulmonary, and hematologic diseases and sleep disorders.
42 ans for studying the role of phytosterols in hematologic diseases and testing therapeutic interventio
43 mal HSC biology, featuring aspects of aging, hematologic disease, and how this circuitry may be explo
44 mycosis fungoides, inflammatory cutaneous or hematologic diseases, and from healthy volunteers.
45  comparable to those of open splenectomy for hematologic diseases, and it appears to retain other pat
46 e a treatment for patients with nonmalignant hematologic diseases, and may tolerize patients to organ
47  type I, which is seen exclusively in clonal hematologic diseases, and type II/III, which is called m
48                                 Several rare hematologic diseases are associated with acquired or inh
49 nd, but diagnostic criteria for MDS or other hematologic diseases are not fulfilled, a condition term
50 the prophylactic transfusion of platelets in hematologic diseases are well described, relatively litt
51 ia is a critical problem that occurs in many hematologic diseases, as well as after cancer therapy an
52 uired severe aplastic anemia (SAA) is a rare hematologic disease associated with significant morbidit
53 es, including cancer (B-H P = 3.75E(-9)) and hematologic disease (B-H P = 8.01E(-8)).
54 otentially curative option for patients with hematologic diseases but is associated with high mortali
55 al curative option for treating a variety of hematologic diseases, but acute and chronic graft-versus
56 opoietic cell transplant (HCT) can cure many hematologic diseases, but it carries the potential risk
57 vectors may be effective in the treatment of hematologic diseases by gene therapy.
58       Pure red-cell aplasia (PRCA) is a rare hematologic disease characterized by anemia, reticulocyt
59           Polycythemia vera (PV) is a clonal hematologic disease characterized by hyperplasia of the
60 juvenile myelomonocytic leukemia, are clonal hematologic diseases characterized by myeloid dysplasia,
61 omes (MDSs) are collections of heterogeneous hematologic diseases characterized by refractory cytopen
62 estigation of how biophysical alterations in hematologic disease collectively lead to microvascular o
63                Index patients presented with hematologic disease consisting of cytopenias (thrombocyt
64           These results, obtained in diverse hematologic disease entities, show that common targets (
65 the-art knowledge of targeting complement in hematologic diseases, focusing on (1) complement biology
66 seases, which are far more numerous than the hematologic diseases for which CAR-Ts have been granted
67 tients referred for elective splenectomy for hematologic disease from March 1992 to March 1995.
68 otein (EGFP) controls, which did not develop hematologic disease (> 200 days).
69 lobinuria (PNH), a rare but life-threatening hematologic disease, has fundamentally improved with the
70 e for cladribine (2CdA) therapy of malignant hematologic diseases have not been determined.
71                              Medications for hematologic diseases have the potential to modulate thes
72 ms is critical for improving the outcomes of hematologic diseases, hematopoietic SC transplantation,
73  shown to be involved in the pathogenesis of hematologic disease in animal models.
74 ividually play a role in the pathogenesis of hematologic disease in mice.
75 alized patient dying with advanced cancer or hematologic disease in which the limitation of life-sust
76 ow as well as for study of hematopoiesis and hematologic diseases in vitro.
77  Thirteen patients showed evolution to other hematologic diseases, including monosomy 7.
78 sordered erythropoiesis is a feature of many hematologic diseases, including sickle cell disease (SCD
79 entiation, and iron overload in a variety of hematologic diseases is associated with excessive bone r
80                  Aplastic anemia, an unusual hematologic disease, is the paradigm of the human bone m
81 inactive granulomata, or even the underlying hematologic disease itself (especially in patients with
82 native for patients with high-risk malignant hematologic diseases, lacking an HLA identical sibling a
83                                              Hematologic diseases may be among the first clinical tar
84 ; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addit
85 take-associated alterations in patients with hematologic disease on triazol antifungal medication.
86 l-Appendicular, Skeletal-Axial, Bone Marrow, Hematologic Diseases, Oncology Clinical trial registrati
87 eukemia (AML) varies as a result of previous hematologic disease or can be explained by differences i
88 % CI, 0.20-0.64; P = 0.003), and presence of hematologic disease (OR, 0.44; 95% CI, 0.24-0.8; P = 0.0
89  have been implicated in the pathogenesis of hematologic diseases other than chronic myelogenous leuk
90                              Among them, the hematologic disease paroxysmal nocturnal hemoglobinuria
91 ause of the association of mastocytosis with hematologic disease, plasma levels were measured for sol
92 ngus, site and extent of IMD, comorbidities, hematologic disease prognosis, and future plans for chem
93 roup) and only 3 allografts were lost due to hematologic disease recurrence (HSCT first n = 1 and KT
94               Only 4 patients expired due to hematologic disease relapse (2 patients in each group) a
95 to analyze the impact of CMV reactivation on hematologic disease relapse in the current era.
96 CMV reactivation had no preventive effect on hematologic disease relapse irrespective of diagnosis.
97 d does not seem to confer protection against hematologic disease relapse.
98 t relapse and especially evolution of clonal hematologic diseases remain problematic.
99 arameters out of normal range as a result of hematologic disease should be included in trials.
100 astic anemia (AA) is its evolution to clonal hematologic diseases such as myelodysplasia (MDS) and le
101 bers has been associated with multiple human hematologic diseases such as neutrophil dysfunction, leu
102 uring an immune response and in premalignant hematologic diseases, such as MDS.
103                                           In hematologic diseases, such as sickle cell disease (SCD)
104 ute promyelocytic leukemia is one of the few hematologic diseases that must be recognized under the m
105 n factors V and VIII (F5F8D) are the 2 known hematologic diseases that result from defects in the end
106 antation mortality is greater than for other hematologic diseases, treatment leads to durable hematol
107                One hundred ten patients with hematologic disease were enrolled.
108 transfused patients with non-immune-mediated hematologic diseases were used as controls.
109 ciations of CH in 200 patients without known hematologic disease who were undergoing THA.
110 topoietic stem cell source for patients with hematologic diseases who can be cured by allogeneic hema
111 rds: CT, CT-Spectral, Skeletal-Axial, Spine, Hematologic Diseases, Whole-Body Imaging, Comparative St
112    Myelodysplastic syndrome (MDS) is an onco-hematologic disease with distinct levels of peripheral b
113 e only curative treatment for many malignant hematologic diseases, with an often critical graft-versu
114   Increasing use of HCT for the treatment of hematologic diseases worldwide translates to an increasi

 
Page Top